Cure My Disease

Don't miss your cure!

 Log in / Sign up

App aims to ease depression and anxiety through guided journaling

NCT ID NCT07126275

Symptom relief Sponsor: Child Mind Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether using a journaling and mood-tracking app called Mirror can reduce symptoms of depression and anxiety in young adults aged 18 to 25. About 500 participants with mild to moderate symptoms will use the app and report their mood changes over 8 weeks. The goal is to see if guided journaling and tracking moods can make people feel better.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 500 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2025

Expected to finish

Aug 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 25 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Prolific users ages 18-25 * Must reside in the U.S. * Must have access to a smart device, and are willing to download an external app (screened by Prolific Academic) * Must complete screening form which consists of the Patient Health Questionnaire (PHQ-2) and the Generalized Anxiety Disorder (GAD-7) Scale. * Must have mild to moderate depressive or anxiety symptoms, as measured by the screening form Exclusion Criteria: \- None

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anxiety symptoms are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anxiety disorder Depression

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anxiety symptoms Depression symptoms

Contacts and locations

Locations

  • Child Mind Institute

    New York, New York, 10022, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.